DNA Script, a pioneer in Enzymatic DNA Synthesis (EDS) for on-demand DNA printing, announced the completion of its Series C financing, raising $200 million of new capital. With this latest financing, DNA Script has raised $315 million since the company was founded in 2014.
Accounts and funds advised by T. Rowe Price Associates and Baillie Gifford participated in the second tranche of the Series C along with Healthcor Management, eureKARE, and Irving Investors. They joined Coatue Management, Catalio Capital Management, Fidelity Management & Research Company LLC, Columbia Threadneedle Investments, Casdin Capital, as well as other investors who participated in the first closing.
Proceeds from this financing will be used to advance the SYNTAX Platform, DNA Script’s first commercial product powered by its proprietary EDS technology. SYNTAX empowers scientists to rapidly print synthetic nucleic acids for genomics and molecular biology applications at the convenience of their lab bench. On-demand printing enables labs to iterate without waiting days or weeks to receive their genetic material from third-party service providers.
“We are thrilled to partner with this world-class group of investors, including new participants Baillie Gifford and T. Rowe Price, who collectively share our vision to increase access to oligo manufacturing to accelerate the bio-revolution,” said DNA Script’s Co-founder and CEO Thomas Ybert. “SYNTAX is the first step toward creating a new paradigm for DNA and RNA synthesis. With the support of our investors, we look forward to continuing to advance this new paradigm to solve some of our largest challenges and advance human health.”